Post-transplant nephrotic syndrome: A comprehensive clinicopathologic study.
them develop nephrotic-range proteinuria [1] [2] [3] [4] [5] [6] [7] [8] . Among many factors that can affect renal graft function, proteinuria of more than 1 g/day is one of the most accurate predictors of graft loss [9, 10] . Nephrotic-range proteinuria is known to portend an even worse prognosis, characterized by a markedly decreased graft survival rate. The one-and five-year graft survival rates in recipients who develop post-Tx nephrotic syndrome (NS) are 75.3% and 37.5%, respectively [3, 4] , compared with 87.5% and 52.5% for those without it [7] .
Despite the high incidence and the prognostic implication of post-Tx NS, many aspects of this syndrome are not known. There are only a limited number of pertinent studies, most of which included both patients with nephrotic and subnephrotic proteinuria, and which were completed before the introduction of newer immunosuppression drugs or international standardization of nomenclature for the pathologic changes in renal transplant biopsies. In fact, the three major studies of post-Tx NS covered the periods between the years of 1963-76, 1967-84, and 1980-88, respectively [1, 2, 7] . Almost all of these studies eliminated cases in which NS developed shortly after Tx or eventually remitted [1, 2, 6, 5] . Because of these considerations, many aspects of post-Tx NS, including its predisposing factors, etiology, associated renal changes, and clinical course are still not completely understood. In addition, how the newer immunosuppressive drugs and more recent approaches to the treatment of proteinuria affect the behavior of post-Tx NS is not well defined. We undertook this study, which comprehensively evaluates all patients with post-Tx NS during a 14-year period, to further characterize this syndrome.
METHODS
Seventy-four cases of post-Tx NS were identified among the kidney transplant recipients at The Methodist Hospital/Baylor College of Medicine, Houston, Texas during a 14-year period from 1988 to 2002. During that time there were 570 renal transplant recipients at the same institute. The clinical follow-up schedule was as followed: twice weekly for the first 6 weeks, weekly for the next 6 weeks, biweekly for the next 6 weeks, triweekly for the next 6 weeks, monthly until the end of the first year, and bimonthly thereafter. In order to study the nature of the NS that develops shortly after Tx, all cases of NS onset were included, regardless of time.
The urine protein level was measured in 24-hour collections by a colorimetric method [11] , and protein excretion during the follow-up period was monitored by the protein/serum creatinine (SCr) ratio in spot morning urine specimens [12] [13] [14] . These methods have been validated previously [12] [13] [14] . Routine urinalysis and urine protein/creatinine ratio was performed for each visit. In the context of post-Tx proteinuria, renal Tx biopsy was performed when the urine protein/creatinine ratio continued to increase in several consecutive follow-up visits, or when this ratio was more than 1.5. NS was defined as the presence of edema, protein excretion of more than 3.0 g/day, hypoalbuminemia, and hyperlipidemia. Seventy-four patients fulfilled these criteria, and their records were reviewed for clinical features, including causes of end-stage renal disease (ESRD), donor status, the course of NS, renal function, conditions that may be related to the development of NS including blood pressure, systemic diseases, infections, response to treatment, and graft outcome. Complete remission of NS was defined as protein excretion of less than 0.5 g/day that persisted during at least two consecutive assays performed at least two weeks apart.
Seventy-three of the 74 patients had at least one transplant biopsy performed within six months of the onset of NS to evaluate its causes. Twenty-seven follow-up biopsies and five graft nephrectomies were performed in 29 patients. The renal transplant biopsies were subjected to light microscopy (LM) with hematoxylin and eosin, periodic acid-Schiff (PAS), and Masson's trichrome stains; immunofluorescent (IF) studies for immunoglobulin (Ig)G, IgM, IgA, C3, C4, kappa and lambda light chains, and electron microscopy (EM). The 1997 Banff classification for renal transplant biopsy [15] was used for diagnostic categorization. The renal biopsy findings were tabulated and correlated with the clinical findings at the time of biopsy and during follow-up.
Differences in proportions were evaluated by chisquare or Fisher exact test as appropriate. Graft survival rates were calculated using the method of Kaplan and Meier, and compared by the log-rank test. Proportional hazards regression model was used for multivariate analysis of survival. Statistica for Windows software was used for the statistical analysis (StatSoft, Inc., Tulsa, OK, USA). Results were considered statistically significant at P < 0.05. 
RESULTS

Renal transplant biopsies
Because the features of post-Tx NS vary among its causes, as recognized by renal Tx biopsy findings, these findings will be described first before reporting the clinical findings and the clinicopathologic correlation.
Initial biopsies
Renal Tx biopsies performed in 73 of 74 patients at an average of 3.2 months after the onset of NS showed chronic allograft nephropathy (CAN) in 31, recurrent glomerular diseases in 15, de novo glomerular diseases in 18, and undetermined glomerulonephritis in 9 patients, in whom the primary renal diseases were unknown.
The common features of the 31 biopsies with CAN were tubular atrophy, interstitial fibrosis, interstitial inflammation, and fibrous or hyaline intimal thickening of the arterial blood vessels of variable severity. However, the glomeruli in these biopsies displayed a spectrum of lesions (Table 1) . Thirteen biopsies showed nonspecific glomerular changes, including global sclerosis or mild ischemic injury characterized by small glomerular size, mild wrinkling, collapse of the glomerular capillaries, and mild focal segmental mesangial sclerosis and hypercellularity. Twelve biopsies showed chronic allograft glomerulopathy characterized by global or segmental thickening of the glomerular capillaries, reduplication of the glomerular basement membrane, and widening of the lamina rara interna, together with mesangial sclerosis and hypercellularity; within this group, focal segmental sclerosis of glomeruli was also seen in four biopsies, and acute glomerulitis in another three biopsies. Six biopsies showed focal segmental sclerosis involving one or more glomeruli; some of the glomeruli in these biopsies displayed nonspecific changes, as described above, but chronic allograft glomerulopathy or the vascular changes characteristic for chronic rejection were not seen.
The 42 biopsies with de novo or recurrent glomerular diseases (Table 1 ) displayed features similar to those diseases in native kidneys. Changes consistent with superimposed CAN were also identified in 25 (59%) of these biopsies. Minimal change disease (MCD) was diagnosed in 5 biopsies. These biopsies showed no significant glomerular changes, except for effacement of foot processes; the tubulointerstitial compartment was normal in three or showed acute rejection and acute cyclosporine A (CsA) toxicity in one each; remission of NS was a requirement for the diagnosis of MCD in the present study.
Biopsy was not performed in one patient in whom NS developed 2 weeks' post-Tx, at which time the serum creatinine (SCr) was 4.4 mg/dL. Antirejection treatment reversed the SCr to 1.1 mg/dL at one month, but NS persisted. At 4 months' post-Tx, the daily protein excretion was 0.1 g, but the SCr was 3.2 mg/dL and a renal Tx biopsy showed acute cell-mediated rejection and normal glomeruli. The patient responded to antirejection therapy, and the NS continued to be in remission until 54 months' post-Tx, when the SCr was 7.5 and NS recurred because of biopsy-documented CAN. Although the cause of the initial episode of NS is not known, it may have been related to MCD.
Follow-up biopsies
Twenty-seven follow-up biopsies and five nephrectomies were performed in 29 patients (Table 2) . Among the 17 with the original diagnoses of CAN, the repeated biopsies still showed CAN, albeit of more advanced degree. The associated glomerular lesions stayed the same in 12 of these biopsies, but progressed in the other five (nonspecific glomerular changes to FSGS in one, nonspecific glomerular changes to FSGS and chronic allograft glomerulopathy in one, FSGS to FSGS with chronic allograft nephropathy in one, and chronic allograft glomerulopathy to chronic allograft nephropathy and FSGS in one). The diagnosis remained the same for the other 10 repeated biopsies (three recurrent FSGS, two IgA nephropathy, two membranous GN, and one each of lupus nephritis, MCD, and de novo FSGS), but the disease process was more severe in many of these biopsies. All five nephrectomy specimens showed severe rejection that obscured the underlying diseases (CAN in three, IgA nephropathy in one, and diabetic nephropathy in one).
Clinical findings and clinicopathologic correlations
Patients. The patients included 29 women and 45 men, with an age range of 16 to 72 years (mean 43). The causes of ESRD, listed in Table 3 , are comparable to those of the general population, indicating that no specific primary renal disease is predisposed to post-Tx NS. The clinical features of patients, separated by the causes of NS, are listed in Table 4 . The cadaveric/living-related donor ratio was 52/22. Six patients had one and three had two previous renal allografts. Delayed graft function was observed in 14 cases (19%). Hypertension was present in 70 (94%). The prevalence of hepatitis B infection was 10/48 (21%), hepatitis C infection 10/44 (23%), and cytomegalovirus (CMV) seropositivity 30/60 (50%). There was no significant difference of the prevalence of these features among different causes of post-Tx NS. 
Features of NS
The time between Tx and onset of NS was widely variable (0.25 to 384 months). However, among different causes, this interval is shortest for CAN (mean 43.9 vs. 56.7, 57.7, and 81.4 months for other groups, P < 0.001) (Fig. 1 ). Thirty-four and 40 cases were encountered in the first and the second halves of the study period, respectively. At the onset of NS, the daily protein excretion was similar among groups (mean 5.4, 5.8, 4.8, and 3.9 g/day). The SCr, however, was highest for CAN (mean 3.6 vs. 2.7, 1.8, and 2.0 mg/dL for other groups).
Treatment
The baseline immunosuppression included CsA, tacrolimus (FK506), sirolimus (SRL), azathioprine (AZA), mycophenolate mofetil (MMF), and prednisone (Pred) in the following combinations: CsA + AZA + Pred (13 patients), CsA + MMF + Pred [15] , CsA + SRL + Pred [8] , FK506 + MMF + Pred [31] , SRL + MMF + Pred [2] , or CsA + Pred [2] . One patient voluntarily discontinued all immunosuppression 7 years before the onset of NS [16] . Seventeen patients had acute rejection before the onset of NS. The types of immunosuppressants and the incidence of acute rejection were not significantly different among the causes of post-Tx NS (Table 5) .
Treatment for NS included angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) alone (18 patients), calcium channel blockers (CaCB) alone [25] , or both medications [31] and increased steroid dose alone [1] . Several patients received these medications for hypertension even before the development of NS. Plasmapheresis was used for three out of four patients with recurrent FSGS.
Remission of NS
At the end of a follow-up of 80 months (range 8 to 420), complete remission of NS was observed in 17 (23%) of all cases after a mean of 9.5 months (range 2 to 28), at which time the mean SCr was 1.7 ± 0.2 mg/dL (range 0.8 to 3.2), compared to 2.7 ± 0.2 mg/dL (range 0.6 to 12.1) at the onset of NS (Table 5) . Once the NS underwent remission, the remission persisted throughout the follow-up period in all except three patients. In one of the patients, the recurrence was caused by biopsy-documented IgA nephropathy with CsA-induced thrombotic microangiopathy, and it went into remission again until last follow-up, when the graft remained functional. In the other two patients, whose initial NS was caused by biopsy-documented and probable MCD (see earlier text), NS, caused by CAN in both, recurred 35 and 49.5 months, respectively, after the initial remission, and it persisted and was associated with graft loss in both. Table 4 shows that the remission rate of post-Tx NS differed among its causes and was lowest (9%) for CAN and highest (47%) for de novo glomerular diseases (P = 0.016), but there is no difference in the duration of NS among causes. Table 6 illustrates the renal biopsy findings in cases of NS, which went into remission. Although MCD was diagnosed in at least 5 biopsies (30%), a broad spectrum of other lesions was also observed. Compared with cases with persistent NS, those with remission showed a significantly higher incidence of de novo GN (53% vs. 17%), a lower incidence of CAN (17% vs. 49%), an earlier onset of NS (39 vs. 59 months), a lower SCr at the onset of NS (2.3 vs. 2.9 mg/dL), and a higher incidence of a treatment which included ACE or ARB. A multivariate analysis showed, however, that remission was independently associated only with etiology (P = 0.002).
Graft outcome
The mean duration of follow-up was 80 months (range 8 to 420), with that for CAN group significantly shorter than those of the other groups. This difference mainly reflects the time of graft loss as end point, and there were more graft losses in the CAN group. Four patients died of nonrenal causes during the follow-up. At the end of follow-up, 31 grafts (42%) remained functional, and 43 (58%) failed after a mean of 21.9 months (range 1 to 63) after the onset of NS. Graft loss was most frequent (Fig. 1) and earliest (Fig. 2) for CAN, followed by those associated with recurrent and de novo glomerular diseases. The five-year graft loss rates for CAN, recurrent, and de novo glomerular diseases were 57%, 36%, and 23%, respectively. The mean duration between the onset of NS and graft loss was 14.4, 33.6, and 40.3 months for CAN, recurrent, and de novo glomerular diseases, respectively. Although the rate of graft loss for the undetermined GN approached that of CAN, in three out of four lost grafts in this group there was advanced CAN in addition to GN. Compared with the functioning grafts (Table 7) , the failed grafts showed a significantly higher incidence of CAN (60% vs. 16%), a lower incidence of de novo GN (12% vs. 46%), an earlier onset of NS (47 vs. 64 months post-Tx), a higher SCr at the onset of NS (3.3 vs. 2.0 mg/dL), a lower incidence of remission of NS (5% vs. 48%), and a higher protein excretion at follow-up (5.1 vs. 2.5/day). Figure 3 shows that, regardless of the cause of NS, the rate of graft survival was significantly better in those in whom the NS remitted (P = 0.004). In the multivariate analysis of factors influencing Abbreviations are: ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; Bx, biopsy; CaCB, calcium channel blockers; CAN, chronic allograft nephropathy; F/M, female/male; GN, glomerulonephritis; NS, nephrotic syndrome; Pro, proteinuria; Scr, serum creatinine; Tx, transplant.
a The primary renal diseases were not known in these cases; b One patient had two reversible episodes of post-transplant nephrotic syndrome. graft survival, only etiology of NS had an independent prognostic value (P < 0.001).
DISCUSSION
The present study reporting post-Tx NS in 13% (74/570) of renal transplant recipients indicates that this is a frequent condition. This incidence, which is higher than reported in most previous studies with a range between 3% to 13.7% [17, 18] , may be related to study design because our study included all patients with postTx NS, whereas only those in whom the NS persisted or developed beyond 1 to 3 months post-Tx were included in previous studies [1, 2, 18] . NS developed within 3 months post-Tx in 14 patients in our study and, if these cases were eliminated, the incidence of post-Tx NS would be 10.5%. These observations indicate that the incidence of post-Tx Ns remains the same over the years, in spite of Most previous studies concur that post-Tx NS caused by recurrent glomerular diseases, de novo glomerular diseases, and a heterogeneous but related group of renal injury unrelated to the former two, for which several names, including transplant glomerulopathy, chronic rejection, CsA vasculopathy, and allograft glomerulopathy have been used [1] [2] [3] [4] [5] [6] [7] [8] . Among these studies, the same name was used to describe different lesions, or the same lesion was reported under different names. This confusion has detracted from a uniform understanding of the real causes of post-Tx NS, as well as the frequency and the biologic significance of these causes.
In the present study, the widely accepted terminology from the 1977 Banff classification on the pathologic changes of renal allografts was used [15] . According to this classification, CAN is the most frequent cause of postTx NS (40%) in our study. These observations corroborate those reported in previous major studies on post-Tx NS, and indicate that its general causes remained the same over the years [1, 2, 7] . Because heavy proteinuria is well known to reflect glomerular injury, the types of glomerular lesion seen in CAN were carefully documented and classified in the present study (Table 1) . We could not find any clinical difference among these glomerular lesions, Abbreviations are: ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; Bx, biopsy; CaCB, calcium channel blockers; CAN, chronic allograft nephropathy; F/M, female/male; GN, glomerulonephritis; NS, nephrotic syndrome; Pro, proteinuria; SCr, serum creatinine; Tx, transplant.
a The primary renal diseases were not known in these cases. b One patient had 2 separate episodes of nephrotic syndrome.
indicating that NS is related to the severe renal injury typical for CAN, rather than a specific type of glomerular lesion encountered in this condition.
De novo and recurrent glomerular diseases were confirmed by this study as the other causes of postTx NS (26% and 20%, respectively). De novo FSGS can be seen in renal transplant in at least two different contexts: (1) as a component of chronic allograft glomerulopathy; or (2) as an isolated finding, which may be associated with mild chronic tubulointerstitial injury, but without obvious features chronic allograft glomerulopathy [19] [20] [21] [22] . Whether these two categories are related or independent entities remains controversial. We, however, are convinced that FSGS unrelated to chronic allograft glomerulopathy may occur. This condition is characterized by focal segmental sclerosis of glomeruli, associated with no significant or only minor nonspecific changes in the remaining glomeruli, absence of features of chronic allograft glomerulopathy, absence of the type of vascular lesions characteristic for vascular chronic rejection, and mild-to-moderate chronic tubulointerstitial nephritis. It may be clinically manifested by nephroticrange proteinuria with mild impairment of renal function. Six such cases were encountered in our studies, and one of them was previously reported [16] . This type of FSGS has also been alluded to in previous reports on post-Tx FSGS [19] [20] [21] [22] . Recognizing this type of lesion may be in keeping with the current thought that chronic glomerular injury in renal transplants may be multifactorial [15] . It may be a result of an immunologic response, which would account for the development of chronic allograft glomerulopathy with focal segmental sclerosis of glomeruli as a component [20] [21] [22] . Alternatively, other conditions, including hyperfiltration, reflecting the presence of a single kidney with potential further impairment by factors such as advanced donor's age, pretransplant ischemia, donor-related nephrosclerosis, or cyclosporine A-induced arteriolopathy may account for the type of FSGS unrelated to an alloreactivity [23] . IgA nephropathy was diagnosed in two patients whose primary diseases were FSGS and hypertensive nephrosclerosis, respectively. Donor-related IgA nephropathy is quite frequent and was reported in 11% and 5.4% of living-related and cadaveric donors, respectively [24, 25] . Without a donor renal biopsy, it is not possible to conclusively determine whether the IgA nephropathy in these two patients was de novo or donor-transmitted. However, several studies have suggested that kidneys with donor-transmitted IgA nephropathy function well and, indeed, IgA disappears a few months post-Tx in repeated biopsies [26] [27] [28] [29] . These considerations suggest that the IgA nephropathy in these two patients was probably de novo. MCD was biopsy-documented in 5 cases (7%), and probably was the cause of NS in another (see earlier text). Some of these cases were previously reported in more detail [30] . These cases share the same clinicopathologic features, including a lack of significant glomerular changes, except for effacement of the foot processes, a lack of chronic tubulointerstitial injury, an early onset of NS (1 week to 4 months post-Tx), a normal or mildly decreased renal function which was readily reversed by antirejection treatment or decreased CsA dose, sustained remission of NS, and functioning grafts at last follow-up. Several isolated cases with features similar to ours have been reported (reviewed in [30] ), and MCD accounted for 2.7% (1/36) [1] , 4% (1/26) [31] , and 5.5% (1/18) [32] in three series of post-Tx NS. Several renal lesions in the early post-Tx period (usually defined as one month), including preservation injury, acute tubular necrosis, or acute rejection may induce proteinuria but spare glomeruli and thus can be confused with MCD on biopsy. However, the proteinuria in these conditions is usually mild (less than 1 g/day) and should decrease rapidly in the following weeks, with complete remission in most cases within a month [33] [34] [35] [36] . Furthermore, MCD developed in livingrelated grafts in two current and at least five previously reported cases [1, [37] [38] [39] [40] [41] , in which preservation injury or acute tubular necrosis was unlikely. MCD in native kidney may be related to undetermined circulating factors, probably lymphokines, which promote transglomerular capillary permeability [42] . Disturbed immunoregulation in renal allograft recipients may lead to activation of selected population of lymphoid cells capable of synthesizing the lymphokine(s) responsible for NS [43] . Although the patients with post-Tx MCD were on several medications, the same types of medication were also used for renal transplant recipients without post-Tx NS or those in whom the post-Tx NS was not caused by MCD. These observations suggest that post-Tx MCD is probably not iatrogenic. These observations suggest that although the nature of de novo MCD is not known, it represents an important but previously underemphasized cause of post-TX NS, with a characteristic clinicopathologic profile including a uniformly good prognosis.
The treatment for post-Tx NS syndrome has not been established. Although inhibition of the renin-angiotensin system with ACEI or ARB has been known to attenuate proteinuria associated with native kidney diseases, especially diabetic nephropathy, its role in the treatment of post-Tx proteinuria has just recently been explored, and the pertinent studies focus on significant but mild proteinuria rather than NS. Dulek et al demonstrated that a 12-week treatment with losartan reduced microalbuminuria in hypertensive renal transplant recipients from a mean of 103 to 47 mcg/min [44] . Suwelack et al showed in a similar group of patients a stable mean protein excretion of 0.52 g/day over a five-year period with quinapril, compared with an increase in protein excretion from 0.34 to 0.72 g/day in those treated with a beta blocker [45] . Antiparmarek et al reported a rate of 75% partial or total remission in 37 renal transplant recipients with protein excretion of 1 g or more a day in response to ACE or ARB. In all these studies, the antiproteinuric effect of ACE or ARB was independent of blood pressure [46] . In contrast, although CaCB has been shown to control postTx hypertension and improve graft survival in both clinical and experimental settings [47, 48] , protein excretion under this regimen was not attenuated, but was actually increased. Sixty-five percent of the patients in the current study were treated with ACEI or ARB, without (24%) or with (41%) CaCB, whereas 33% of them received CaCB only. ACEI/ARB was used more frequently than CaCB in patients with remission (83% vs. 17%), compared with those in whom the NS persisted (60% vs. 38%). These observations suggest that pharmacologic inhibition of the renin-angiotensin system may attenuate post-TX protein excretion, regardless of its magnitude.
Remission of post-Tx NS caused by recurrent FSGS, the most frequent cause of this syndrome in pediatric population, has been well studied, and this outcome was reported in up to 50% of cases [49] [50] [51] . However, little is known about the remission of post-Tx NS resulting from other causes. There are only isolated reported cases in which post-Tx NS caused by de novo MCD [30] , acute glomerulitis [52, 53] , acute rejection [7, 53] , chronic rejection [7] , de novo or recurrent membranous GN [54] [55] [56] , or foscarnet-induced GN [57] underwent remission. Most series on post-Tx proteinuria/NS included only cases with persistent proteinuria [2, 5, 6, 18, 31] . Because of these considerations, the features of the subset of post-Tx NS that is destined to undergo remission are not known. The current study found that post-Tx NS underwent remission in 23% of all cases, several of which were reported in detail elsewhere [58] . This incidence is between those mentioned briefly by Vathsala et al (11.3%) and Yildiz et al (47%), which, to the best of our knowledge, are the only two studies providing these data [7, 8] . The collective observations suggest that remission of post-Tx NS is not unusual. As reported previously, we found no significant differences in the age, sex, spectrum of primary renal diseases, cadaveric/living-related donor ratio, or the frequency of hypertension, hepatitis B, hepatitis C, or CMV seropositivity, or the immunosuppression regimens between patients in whom the NS persisted or remitted [58] . However, these two groups did show differences in the renal biopsy findings, the onset of NS, the treatment for NS, and the chance of graft survival. The NS, which underwent remission, had an earlier onset than those that persisted (mean 39.3 vs. 59.5 months) and, in fact, the onset was within three months post-Tx in 47% of the cases. These observations indicate that early onset is an important predictor of remission. The renal biopsy findings are another important predictor of remission because recurrent or de novo glomerular diseases are significantly more frequent in the remitted group as compared with the persistent one (47% vs. 17%, P = 0.031), and almost a half and a third of cases of NS caused by recurrent and de novo glomerular diseases, respectively, underwent remission Although a spectrum of renal lesions was found to be associated with remission (Table 6 ), MCD encountered in five cases (30%) is the most frequent one and the early onset of remitted NS largely reflects the predominance of MCD within this time frame (Table 7 ). The remission of NS encountered in all cases of MCD may be akin to the behavior of the same disease in the native kidney [59] . The remission of NS in one out of four cases of recurrent FSGS (25%) reflects the known behavior of NS associated with this condition, and may be related to therapy including plasmapheresis to remove a putative circulating glomerular permeability factor suspected to be of pathogenetic importance for FSGS in general [49, 50] . On the other hand, how the NS associated with other diseases listed in Table 6 underwent remission is not clear because the NS associated with these diseases is in general persistent. Several Tx biopsies in these cases showed acute glomerulitis or acute cell-mediated rejection, in addition to the main glomerular lesions. It is possible that acute glomerulitis or acute rejection, which by itself has been reported to be associated with mild and infrequent proteinuria [7, 52, 53] , may accentuate the proteinuric effect of other glomerular lesions. Because they are reversible in response to immunosuppression, their presence may be partly responsible for the remission of NS. Alternatively, remission may be related to treatment because most of these patients were treated with ACEI and/or ARB. One interesting feature of the remitted NS is that the remission continued in the vast majority of cases, and this predicted a far superior graft outcome as compared with the persistent group (2-, 5-and 10-year graft survivals: 100%, 82%, and 82% vs. 83%, 54%, and 25%). These observations corroborate previous reports [3, 5, 6, 7] and support recent multivariate analyses, which showed that, among numerous factors which can influence renal graft outcome, heavy proteinuria is the most [10] or the second most (behind arterial resistance) important [9] .
CONCLUSION
The overall five-year graft loss rate of 48% in our study ( Fig. 1) was somewhat better than those previously reported, which ranged from 60% to 77% [1, 2, 7] . This difference, however, may be caused by the inclusion of those with remission of NS because if they are eliminated the rate was 56% (Fig. 2) . These observations indicate that the risk of graft loss incurred by persistent post-Tx NS has not improved over the years. Although post-Tx NS portends poor graft outcome in general, our study suggests the prognosis is quite different among subgroups of patients. Apart from the general agreement that remission of proteinuria implies a good outcome [3, 5, 6, 7] , the impact of other factors remains in dispute. Cheigh et al originally suggested that recurrent GN carried the worst prognosis, followed by "allograft glomerulopathy" and de novo GN [1] . Vatsala et al reported a worse prognosis for the "non GN" than the "GN" group [7] . Peddi et al and First et al found no difference in graft survival among causes of post-Tx heavy proteinuria [2, 6] . Our study provides strong evidences to suggest that the two most important prognostic factors for post-Tx NS are its causes and whether it remits or persists. Among the different causes of post Tx NS, CAN is associated with the highest rate of graft loss (84%), the lowest rate of remission (9%), and the shortest duration (14.4 months) from the onset of NS to graft loss (Table 4 and Fig. 1 ). Although poor graft survival in our study was significantly associated with an early onset of NS, a higher SCr level at onset of NS, and the severity of chronic tubulointerstitial injury, these factors were also most pronounced for CAN, and they may not be independent predictors, as shown by a multivariate analysis.
